Physician profile
Stephen Michael Testa
NPI 1902291438
$3,626.72
in general payments reported to CMS, 2019-2025
20 companies · $538 in 2025
The $538 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117 · 2021: $372 · 2022: $858 · 2023: $828 · 2024: $913 · 2025: $538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,251 · Education: $28.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,250.97 |
| Education | $28.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $778.99 | 2021-2024 | Skyrizi, Rinvoq, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $488.82 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $483.13 | 2021-2025 | Xifaxan, Trulance |
| Genzyme Corporation | $271.10 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $265.53 | 2022-2025 | Dupixent |
| Gilead Sciences, INC. | $247.61 | 2019-2022 | |
| Daiichi Sankyo INC. | $140.49 | 2022-2025 | Injectafer |
| Merck Sharp & Dohme LLC | $139.17 | 2021-2023 | Dificid |
| Medtronic, INC. | $126.22 | 2025 | Endoflip |
| Janssen Biotech, INC. | $103.56 | 2024-2025 | Stelara, Simponi Aria, Tremfya |
| Celgene Corporation | $101.16 | 2022-2024 | Zeposia |
| Ardelyx, INC. | $92.92 | 2023-2025 | Ibsrela |
| Celltrion USA INC. | $80.66 | 2024-2025 | Vegzelma, Zymfentra |
| Nestle Healthcare Nutrition INC. | $80.65 | 2022 | |
| Lilly USA, LLC | $79.61 | 2024-2025 | Omvoh |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $47.73 | 2023 | Movantik, Aemcolo, Talicia |
| Madrigal Pharmaceuticals | $34.12 | 2025 | Rezdiffra |
| Amgen INC. | $30.47 | 2023 | Amjevita, Avsola |
| Intercept Pharmaceuticals, INC. | $20.73 | 2024 | |
| Pfizer INC. | $14.05 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Testa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.